143 related articles for article (PubMed ID: 34860936)
1. Evaluation of Lipid Profile and Residual Cardiovascular Risk in Patients Prior to Initiation of Niaspan Therapy.
Islam S; Danwada R; Ganguli M; Espaillat R; Jarvis M; Bacher HP
J Pharm Technol; 2018 Feb; 34(1):3-8. PubMed ID: 34860936
[No Abstract] [Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.
Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
Neth J Med; 2004; 62(7):229-34. PubMed ID: 15554597
[TBL] [Abstract][Full Text] [Related]
4. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
Capuzzi DM; Guyton JR; Morgan JM; Goldberg AC; Kreisberg RA; Brusco OA; Brody J
Am J Cardiol; 1998 Dec; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666
[TBL] [Abstract][Full Text] [Related]
6. Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin.
Byrd C; Mowrey KA
Am J Health Syst Pharm; 2010 Dec; 67(23):2038-42. PubMed ID: 21098376
[TBL] [Abstract][Full Text] [Related]
7. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).
Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
Int J Clin Pract; 2007 Nov; 61(11):1914-21. PubMed ID: 17935550
[TBL] [Abstract][Full Text] [Related]
8. Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
Vasc Health Risk Manag; 2007; 3(4):467-79. PubMed ID: 17969377
[TBL] [Abstract][Full Text] [Related]
9. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
Morgan JM; Capuzzi DM; Guyton JR
Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
[TBL] [Abstract][Full Text] [Related]
10. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE
J Am Coll Cardiol; 2013 Oct; 62(17):1580-4. PubMed ID: 23916935
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein apheresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
Tóth PP; Potter D; Ming EE
J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
[TBL] [Abstract][Full Text] [Related]
13. Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome.
Koncsos P; Fülöp P; Juhász I; Bíró K; Márk L; Simonyi G; Paragh G
Wien Klin Wochenschr; 2016 Dec; 128(23-24):858-863. PubMed ID: 27380508
[TBL] [Abstract][Full Text] [Related]
14. Lipid therapy utilization rates in a managed-care mixed dyslipidemia population.
Toth PP; Zarotsky V; Sullivan JM; Laitinen D
J Clin Lipidol; 2008 Oct; 2(5):365-74. PubMed ID: 21291762
[TBL] [Abstract][Full Text] [Related]
15. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
16. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
Goldberg AC
Am J Cardiol; 1998 Dec; 82(12A):35U-38U; discussion 39U-41U. PubMed ID: 9915661
[TBL] [Abstract][Full Text] [Related]
18. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
19. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.
Arsenault BJ; Rana JS; Stroes ES; Després JP; Shah PK; Kastelein JJ; Wareham NJ; Boekholdt SM; Khaw KT
J Am Coll Cardiol; 2009 Dec; 55(1):35-41. PubMed ID: 20117361
[TBL] [Abstract][Full Text] [Related]
20. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
